EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation

Luca Quartuccio, Martina Fabris, Sara Salvin, Marta Maset, Ginevra De Marchi, Salvatore De Vita

International Journal of Rheumatology · 2009

DOI: 10.1155/2009/424935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatology, 2009. Verfasst von Luca Quartuccio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Clinic, DPMSC, Azienda Ospedaliero Universitaria "S. Maria della Misericordia", University of Udine, 33100 Udine, Italy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lachrymal glands, and frequently accompanied by systemic symptoms. A subgroup of SS patients develops malignant B cell non-Hodgkin's lymphoma (NHL), usually of the mucosa-associated lymphoid tissue (MALT) type and very often located in the major salivary glands. Currently, there is a lack of evidence-based intervention therapy which may influence SS-related chronic inflammation and lymphoproliferation. B cells are involved in the pathogenesis of SS, and B cell downregulation may lead to a decrease of disease activity. Rituximab (RTX), a chimeric monoclonal antibody targeting the CD20 antigen on the B cell surface, has been successfully investigated in other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, ANCA-associated vasculitis, and mixed cryoglobulinemic syndrome. Preliminary experiences of RTX therapy in SS patients with or without a lymphoproliferative disorder suggest that SS patients with more residual exocrine gland function might better benefit from RTX. Efficacy of RTX in SS-associated B-cell lymphoma, mainly in low-grade salivary gland lymphomas, remains an open issue.

Autor:innen und Institutionen

  • Rheumatology Clinic, DPMSC, Azienda Ospedaliero Universitaria "S. Maria della Misericordia", University of Udine, 33100 Udine, Italy.

Zitieren

APA

Quartuccio, L., Fabris, M., Salvin, S., Maset, M., De Marchi, G., & De Vita, S. (2009). Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation. International Journal of Rheumatology. https://doi.org/10.1155/2009/424935

Vancouver

Quartuccio L, Fabris M, Salvin S, Maset M, De Marchi G, De Vita S. Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation. International Journal of Rheumatology. 2009. doi:10.1155/2009/424935

BibTeX
@article{Quartuccio2009,
  author = {Quartuccio, Luca and Fabris, Martina and Salvin, Sara and Maset, Marta and De Marchi, Ginevra and De Vita, Salvatore},
  title = {Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation},
  journal = {International Journal of Rheumatology},
  year = {2009},
  doi = {10.1155/2009/424935}
}
Kostenlos starten →